e-learning
resources
Virtual 2021
05.09.2021
Biomarkers and e-health in idiopathic interstitial pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease.
C. Ihuoma (Edinburgh, United Kingdom), A. Przybylski (Edinburgh, United Kingdom), C. Boz (Edinburgh, United Kingdom), F. Li (Edinburgh, United Kingdom), E. Van Beek (Edinburgh, United Kingdom), N. Hirani (Edinburgh, United Kingdom)
Source:
Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Session:
Biomarkers and e-health in idiopathic interstitial pneumonia
Session type:
E-poster
Number:
386
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Ihuoma (Edinburgh, United Kingdom), A. Przybylski (Edinburgh, United Kingdom), C. Boz (Edinburgh, United Kingdom), F. Li (Edinburgh, United Kingdom), E. Van Beek (Edinburgh, United Kingdom), N. Hirani (Edinburgh, United Kingdom). Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease.. 386
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 327s
Year: 2006
KL-6 is a useful serum biomarker for early detection of interstitial lung disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Year: 2012
Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis
Source: Eur Respir J 2016; 48: 1612-1621
Year: 2016
Elucidating progression of early cystic fibrosis lung disease
Source: Eur Respir J, 50 (5) 1701916; 10.1183/13993003.01916-2017
Year: 2017
Clinical and molecular analysis of lung cancer associated with fibrosing and diffuse interstitial lung disease.
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
KL-6 as a potential therapeutic biomarker in fibrosing interstitial lung diseases
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options
Year: 2021
Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Markers of pulmonary vascular compromise predict survival in interstitial lung disease (ILD)
Source: Annual Congress 2008 - Clinical aspects of interstitial lung disease
Year: 2008
Pertechnegas lung clearance in different forms of interstitial lung disease
Source: Eur Respir J 2002; 19: 31-36
Year: 2002
The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Biological- and imaging biomarkers of edema and fibrosis in a rat model of drug-induced interstitial lung disease (DIILD)
Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis
Year: 2019
Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease
Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020
Year: 2020
Biomarkers for interstitial lung disease
Source: International Congress 2016 – ME1 Biomarkers for interstitial lung disease
Year: 2016
Molecular mechanisms of lung tissue remodeling in progression of idiopathic pulmonary fibrosis
Source: Annual Congress 2010 - Emerging mechanisms in lung injury
Year: 2010
Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Year: 2020
Prognostic factors of interstitial lung disease associated with primary Sjögren's syndrome
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage
Source: International Congress 2016 – Orphan diseases I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept